Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE Treatment with efavirenz-induced hypercholesterolemia and hepatic steatosis in mice but deficiency of hepatic PXR abolished these adverse effects. 30677459 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE In conclusion, our findings provide new insight into the molecular mechanisms of steatosis induction by triazole fungicides and identify PXR as a critical mediator of this process. 30989312 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE Of note, PXR deficiency suppressed these changes and steatosis. 29123032 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE We have shown that PXR promotes chronic ethanol (EtOH)-induced steatosis. 29431616 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE Cyproconazole dose-dependently activated RARα and PXR, two molecular initiating events in the steatosis AOP. 29995386 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE Overall, our results uncover SLC13A5 as a novel target gene of PXR and may contribute to drug-induced steatosis and metabolic disorders in humans. 25628225 2015
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease CTD_human In summary, our data suggest that activation and knockdown of PXR in human hepatic cells promote de novo lipogenesis and steatosis by induction of the SREBP1 pathway and AKR1B10-mediated increase of ACC activity, respectively, thus providing mechanistic explanations for a putative dual role of PXR in the pathogenesis of steatohepatitis. 25182422 2015
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE In summary, our data suggest that activation and knockdown of PXR in human hepatic cells promote de novo lipogenesis and steatosis by induction of the SREBP1 pathway and AKR1B10-mediated increase of ACC activity, respectively, thus providing mechanistic explanations for a putative dual role of PXR in the pathogenesis of steatohepatitis. 25182422 2015
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.380 Biomarker disease BEFREE Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice. 22790967 2012